Annual influenza vaccination of patients with cardiovascular diseases and changes in hemagglutinin antibody titers: 3-year follow-up data

Abstract

BACKGROUND: Seasonal influenza vaccination is recommended for patients with cardiovascular diseases. Low vaccination coverage among these patients is due to insufficient knowledge about vaccine efficiency and its regular annual use.

This work aimed to study the repeated 6-month changes in hemagglutinin antibody titers (AT) for 3 years in patients with cardiac pathology in a comparative study of influenza preventive vaccination.

MATERIALS AND METHODS: Analysis of ATs obtained based on the hemagglutination-inhibition test (HAI) was performed in 235 of 817 participants in a prospective follow-up. Blood sampling was performed at baseline, before the vaccination, and 6 months after, and at the same term in unvaccinated patients in the 2012–2013 and 2014–2015 seasons, respectively. The seropositive and seronegative responses to vaccination or acute respiratory or influenza infection were used, according to the reference values of seroconversion and seroprotection and the fact of seroconversion. Multiple regression analysis with a logarithmic scale was used to assess the vaccine effectiveness indices.

RESULTS: With vaccination coverage of at least 40% against seasonal influenza within 3 years, the trends of a decrease in seropositive and an increase in seronegative responses in the vaccination group and its reverse nature in the comparison group were determined by traditional analysis. Using logarithmic calculation, an increase in HAI AT seroconversion was revealed over a 3-year follow-up period. It was characterized by a homogeneous serological response at annual vaccination and heterogeneous with a higher serological response in cases without vaccination (p = 0.002 for H1N1 and p = 0.005 for H3N2, respectively). This trend can be determined by a higher and more stable prevaccination level of HAI AT than the same residual level of AT among unvaccinated patients.

CONCLUSION: During long-term cardiac studies, the logarithmic calculation in interpreting the results of HAI AT overcomes the limitations of the traditional analysis of assessing the efficiency of the annual influenza vaccine. Further serological programs are required to better understand the role of routine seasonal influenza vaccination in preventing morbidity and mortality of patients with cardiovascular diseases.

Keywords

seasonal influenza / vaccine efficacy / annual repeated vaccination / hemagglutinin antibody titers / revaccination / cardiovascular diseases / secondary prevention

References

[1] Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association / American College of Cardiology. J Am Coll Cardiol 2006;48(7):1498-1502. doi: 10.1016/j.jacc.2006.09.004.

[2] Davis M.M., Taubert K., Benin A.L., et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association / American College of Cardiology. J Am Coll Cardiol 2006;48(7):1498-1502. doi: 10.1016/j.jacc.2006.09.004.

[3] Committee for Proprietary Medicinal Products (CPMP): Note for guidance on harmonization of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit (EMEA), CPMP/BWP/214/96. London; 1997.

[4] Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611-2618. doi: 10.1056/NEJMoa041747.

[5] Smeeth L., Thomas S.L., Hall A.J., et al. Risk of Myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611-2618. doi: 10.1056/NEJMoa041747.

[6] Le Bras MH, Barry AR. Influenza vaccination for secondary prevention of cardiovascular events: a systematic review. Can J Hosp Pharm. 2017;70(1):27-34.

[7] LeBras M.H., Barry A.R. Influenza vaccination for secondary prevention of cardiovascular events: a systematic review. Can J Hosp Pharm. 2017;70(1):27-34.

[8] Reshetnikov OV, Kurilovich SA, Nikitin YuP. A possible role of influenza virus in atherosclerosis-associated diseases: is prevention effective? Atherosclerosis. 2012;8(1):27-35. (In Russ).

[9] Решетников О.В., Курилович С.А., Никитин Ю.П. Возможная роль вируса гриппа при атеросклероз-ассоциированых заболеваниях: насколько эффективна превенция? // Атеросклероз. –2012. – Т.8. – №1. – С. 27−35.

[10] Sridhar S, Begom S, Hoschler K, et al. Longevity and determinants of protective humoral immunity after pandemic influenza infection. Am J Respir Crit Care Med. 2015;191(3):325-332. doi: 10.1164/rccm.201410-1798OC.

[11] Sridhar S., Begom S., Hoschler K., et al. Longevity and determinants of protective humoral immunity after pandemic influenza infection. Am J Respir Crit Care Med. 2015;191(3):325-332. doi: 10.1164/rccm.201410-1798OC.

[12] Rukovodstvo po provedeniyu klinicheskikh issledovaniy lekarstvennykh sredstv (immunobiologicheskiye lekarstvennyye preparaty). Part two. Ed. by A.N. Mironov. Moscow: Grifi K; 2013. 212 р. (In Russ).

[13] Руководство по проведению клинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Часть 2 / Под ред. А.Н. Миронова. – М.: Гриф и К, 2013. – 212 с.

[14] Belongia EA, Skowronsky DM, McLean HQ, et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16(7):723-736. doi: 10.1080/14760584.2017.1334554.

[15] Belongia E.A., Skowronsky D.M., McLean H.Q., et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16(7):723-736. doi: 10.1080/14760584.2017.1334554.

[16] Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. PNAS. 1999;96(24):14001-14006. doi: 10.1073/pnas.96.24.14001.

[17] Smith D.J., Forrest S., Ackley D.H., Perelson A.S. Variable efficacy of repeated annual influenza vaccination. PNAS. 1999;96(24):14001-14006. doi: 10.1073/pnas.96.24.14001.

[18] Gurevich VS, Pleskov VM, Levaia MV, et al. Influenza virus infection in progressing atherosclerosis. Kardiologiia. 2002;42(7):21-24. (In Russ).

[19] Гуревич В.С., Плесков В.М., Левая М.В., и др. Инфекция вирусами гриппа при прогрессирующем атеросклерозе //Кардиология. – 2002. – Т.42. – №7. – С. 21−24.

[20] Auer J, Leitinger M, Berent R, et al. Influenza A and B IgG seropositivity and coronary atherosclerosis assessed by angiography. Heart Disease. 2002;4(6):349-354. doi: 10.1097/01.HDX.0000038560.97526.1D.

[21] Auer J., Leitinger M., Berent R., et al. Influenza A and B IgG seropositivity and coronary atherosclerosis assessed by angiography. Heart Disease. 2002;4(6):349-354. doi:10.1097/01.HDX.0000038560.97526.1D.

[22] Guan X, Yang W, Sun X, et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflamm Res. 2012;61(6):591-598. doi: 10.1007/s00011-012-0449-3.

[23] Guan X., Yang W., Sun X., et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. InflammRes. 2012;61(6):591-598. doi: 10.1007/s00011-012-0449-3.

[24] Brydak LB, Romanowska M, Nowak I, et al. Antibody response to influenza vaccine in coronary artery disease: A substudy of the FLUCARD study. Med Sci Monit. 2009;15(7):PH85-91. doi: 10.1164/rccm.201410-1798OC.

[25] Brydak L.B., Romanowska M., Nowak I., et al. Antibody response to influenza vaccine in coronary artery disease: A substudy of the FLUCARD study. Med Sci Monit. 2009;15(7):PH85-91. doi: 10.1164/rccm.201410-1798OC.

[26] Petrie JG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect. Dis. 2015;212(12):1914-1922. doi: 10.1093/infdis/jiv313.

[27] Petrie J.G., Naleway A., Fry A.M., et al. Effects of repeated annual inactivated influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect.Dis. 2015;212(12):1914-1922. doi: 10.1093/infdis/jiv313.

[28] Ohmit ES, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2015;211(10):1519-1528. doi: 10.1093/infdis/jiu650.

[29] Ohmit E.S., Petrie J.G., Malosh R.E., et al. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2015;211(10):1519-1528. doi: 10.1093/infdis/jiu650.

[30] Ohmit ES, Petrie JG, Malosh RE, et al. Substantial influenza vaccine effectiveness in households with children during the 2013-2014 influenza season, when 2009 pandemic influenza A(H1N1) virus predominated. J Infect Dis. 2016;213(8):1229-1236. doi: 10.1093/infdis/jiv563.

[31] Ohmit E.S., Petrie J.G., Malosh R.E., et al. Substantial influenza vaccine effectiveness in households with children during the 2013-2014 influenza season, when 2009 pandemic influenza A(H1N1) virus predominated. J Infect Dis. 2016;213(8):1229-1236. doi:10.1093/infdis/jiv563.

[32] Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009(H3N2)-like virus during 2010−2011. Vaccine. 2016;34(7):981-988. doi: 10.1093/infdis/jiv563.

[33] Thompson M.G., Naleway A., Fry A.M., et al. Effects of repeated annual inactivated influenza vaccination among healthcare personnel on serum hemagglutinin inhibition antibody response to A/Perth/16/2009(H3N2)-like virus during 2010−2011. Vaccine. 2016;34(7):981-988. doi: 10.1093/infdis/jiv563.

[34] Delabre RM, Salez N, Lemaitre M, et al. Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study. Vaccine. 2015;33(49):7015-7021. doi: 10.1080/14760584.2017.1334554.

[35] Delabre R.M., Salez N., Lemaitre M., et al. Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study. Vaccine. 2015;33(49):7015-7021. doi: 10.1080/14760584.2017.1334554.

[36] Delabre RM, Salez N, Lapidus N, et al. Immunity against influenza A(H1N1) infection is determined by age at the time of initial strain circulation. Epidemiol Infect. 2017;145(1):141-147. doi: 10.1080/14760584.2017.1334554.

[37] Delabre R.M., Salez N., Lapidus N., et al. Immunity against influenza A(H1N1) infection is determined by age at the time of initial strain circulation. Epidemiol Infect. 2017;145(1):141-147. doi: 10.1080/14760584.2017.1334554.

[38] Steg PhG, Ducrocq G. Future of the prevention and treatment of coronary artery disease. Circ J. 2016;80(5):1067-1072. doi: 10.1253/circj.CJ-16-0266.

[39] Steg Ph.G., Ducrocq G. Future of the prevention and treatment of coronary artery disease. Circ J. 2016;80(5):1067-1072. doi: 10.1253/circj.CJ-16-0266.

[40] Platonova EV, Gorbunov VM, Belova EN, et al. Vaccination prevention seasonal influenza in patients with cardiovascular diseases. Aspects of the three-year follow-up: vaccination coverage and safety evaluation. The Russian journal of preventive medicine. 2015;18(6):13-18. (In Russ). doi: 10.17116/profmed201518613-18.

[41] Платонова Е.В., Горбунов В.М., Белова Е.Н., и др. Вакцинопрофилактика сезонного гриппа у больных с сердечно-сосудистыми заболеваниями. Аспекты трехлетнего наблюдения: охват вакцинацией и оценка ее безопасности // Профилактическая медицина. – 2015. – Т.18. – №6. – С.13−18. doi: 10.17116/profmed201518613-18.

[42] Voytsekhovskaya EM, Vakin VS, Vasil’yeva AA, et al. Rezul’taty analiza immunogennosti novoy grippoznoy vaktsiny Grippol plyus. Epidemiology & Vaccinal prevention. 2009;(1):40-45. (In Russ).

[43] Войцеховская Е.М., Вакин В.С., Васильева А.А., и др. Результаты анализа иммуногенности новой гриппозной вакцины Гриппол плюс // Эпидемиология и вакцинопрофилактика. – 2009. – №1. – С. 40−45.

[44] Nauta JJ. Eliminating bias in the estimation of the geometric mean of HI titres. Biologicals. 2006;34(3):183-186. doi: 10.1016/j.biologicals.2005.09.001.

[45] Nauta J.J. Eliminating bias in the estimation of the geometric mean of HI titres. Biologicals. 2006;34(3):183-186. doi: 10.1016/j.biologicals.2005.09.001.

[46] Loukov D, Naidoo A, Bowdish DM. Immunosenescence: implications for vaccination programs in the elderly. Vaccine: Development and Therapy. 2015;5:17-29. doi: 10.2147/VDT.S63888.

[47] Loukov D., Naidoo A., Bowdish D.M. Immunosenescence: implications for vaccination programs in the elderly. Vaccine: Development and Therapy. 2015;5:17-29. doi: 10.2147/VDT.S63888.

[48] Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;(24):1159-1169. doi: 10.1016/j.vaccine.2005.08.105.

[49] Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;(24):1159-1169. doi: 10.1016/j.vaccine.2005.08.105.

[50] Mosterin HA, McElhaney J, Fonville JM, et al. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine. 2016;34(4):540-546. doi: 10.1016/j.vaccine.2015.11.058.

[51] Mosterin H.A., McElhaney J., Fonville J.M., et al. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine. 2016;34(4):540-546. doi: 10.1016/j.vaccine.2015.11.058.

[52] Skowronski DM, Hottes TS, McElhaney JE, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Inf Diseas. 2011;203(2):158-167. doi: 10.1093/infdis/jiq039.

[53] Skowronski D.M., Hottes T.S., McElhaney J.E., et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Inf Diseas. 2011;203(2):158-167. doi: 10.1093/infdis/jiq039.

[54] Boytsov SA, Loukianov MM, Platonova EV, et al. Efficiency of influenza vaccination in patients with circulatory system diseases under dispensary observation in outpatient clinics: prospective follow-up monitoring data. Rational pharmacotherapy in cardiology. 2016;12(6):703-710. (In Russ). doi: 10.20996/1819-6446-2016-12-6-703-710.

[55] Бойцов С.А., Лукьянов М.М., Платонова Е.В., и др. Оценка эффективности вакцинопрофилактики гриппа по данным проспективного контроля у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения // Рациональная фармакотерапия в кардиологии. – 2016. – Т.12. – №6. – С. 703−710. doi: 10.20996/1819-6446-2016-12-6-703-710.

RIGHTS & PERMISSIONS

Eco-vector